Sobi Pays $100m Upfront For Selecta Gout Drug
Set To Challenge Horizon’s Krystexxa
Executive Summary
Swedish Orphan Biovitrum has taken a stake in Selecta and got access to SEL-212, which it is hoping will win a head-to-head trial against Horizon's Krystexxa, the gold standard for chronic refractory gout.
You may also be interested in...
Sobi Eyes International Expansion With Growing Late-Stage Pipeline
Sobi is extending its reach in international markets including Russia and China and expects its late-stage R&D pipeline to drive growth.
Sobi's Revenues Decline 3% In Second Quarter, Signs Of Return To Normality In June
Swedish Orphan Biovitrum’s financial performance in the second quarter was held back by COVID-19 related events, but it has left its financial guidance unchanged for 2020.
Deal Watch: GSK Invests In Early-Stage Synthetic Lethality Programs At Ideaya
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.